1GLOBAL
11.7.2024 10:01:34 CEST | Business Wire | Press release
1GLOBAL, a top-tier mobile virtual network operator (MVNO) today announced a strategic partnership with Verint to transform compliance across the financial services and trading sectors to upgrade mobile compliance recording solutions for financial institutions throughout the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711072434/en/
1GLOBAL and Verint partner to offer enhanced Mobile Compliance Recording worldwide (Graphic: Business Wire)
Through this new alliance, 1GLOBAL will now provide all of its global clients with trusted cloud-based recording solutions supported by Verint Financial Compliance. Professionals with compliance obligations can increase their productivity and further their capabilities with voice transcription featuring keyword searching, alerting and meeting summaries.
1GLOBAL clients will also be able to reliably conform with compliance and trade surveillance policies under MiFID II, Dodd-Frank, and MAR / MAD II (among others) to help avoid non-compliance fines and penalties. This new toolset will accelerate compliance audits and easily provide regulatory agencies with complete records of trade-related interactions in a timely manner. Building in these efficiencies reduces costs for financial organizations by leveraging simplified administration, streamlined conversation retrieval, automated rules, and a wide set of external storage integrations on one single contract.
"Partnering with Verint enables us to offer our customers access to the most innovative cloud-based recording solutions on the market,” said Siobhan Thompson, Head of 1GLOBAL Compliance. “Compliance in the cloud is key to 1GLOBAL's strategy. Our partnership with Verint and their VFC platform for our cloud hosting is a testament to that. Verint's cutting edge technology coupled with 1GLOBAL's leading mobile recording capabilities provides customers with assured compliance capabilities as well as increased productivity and analytics.”
“Combining the 1GLOBAL mobile voice and SMS capture capability with the core Verint solution is a critical part of the joint strategy to align all communications into a user-centric view,” says Verint’s John Bourne, Senior VP Global Channels & Alliances. “The integration will provide customers with more control, increased data completeness and the ability to proactively expose compliance anomalies.”
More information on 1GLOBAL’s compliance solution can be found at https://www.1global.com/compliance
About 1GLOBAL
1GLOBAL are market leaders in digital transformation, offering a comprehensive suite of products engineered to facilitate global connectivity at any scale. From truly borderless global business roaming to financial compliance and recording, each solution represents a commitment to excellence.
Started in 2022 by Hakan Koç, co-founder and former co-CEO of AUTO1 Group, 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognised GSMA-accredited global mobile network. Headquartered in London, with an R&D hub in Lisbon, they have now grown to include over 400 employees across 12 countries and are a fully regulated MVNO in nine of them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711072434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom